The honest answer has two halves that point in different directions, and the useful part is knowing which half applies to which period.<\/p>\n
Over the longer term, losing weight generally moves uric acid in the right direction and reduces attacks.<\/strong> Over the weeks and months when the weight is actually coming off, transient increases in uric acid and flares have been described. The risky window is the losing, not the having lost.<\/p>\n A systematic review of longitudinal studies in people with gout, published in Annals of Rheumatic Diseases in 2017, looked at weight loss by various methods. Across the studies, uric acid fell and most showed reduced attack frequency. But the review also noted that temporary increases in attacks tended to occur in the short term after bariatric surgery, and that unfavourable effects may occur during the weight-loss period itself.<\/p>\n Worth knowing how strong that is: the review graded its own evidence as low to moderate, and it was largely observational. So the direction is reasonably supported and the precision is not.<\/p>\n The mechanism behind the transient rise is old physiology rather than anything to do with these medications. When the body shifts toward burning fat, ketone bodies rise, and they compete with uric acid for handling in the kidney. Less uric acid gets excreted, and levels go up for a while. This has long been described with fasting, very low calorie diets and ketogenic diets.<\/p>\n Less than you would like, and the signals conflict.<\/p>\n A post hoc analysis of a large randomized tirzepatide trial found that uric acid fell<\/strong> over 72 weeks, by roughly 0.7 to 1.0 mg\/dL depending on dose against about 0.2 on placebo, so a placebo-adjusted reduction of somewhere between half and eight tenths of a point. Weight reduction accounted for most of that effect. That is the strongest evidence available and it points toward benefit.<\/p>\n Against that, a four-patient case series published in 2026 described people whose uric acid rose, some with acute gout attacks, within three to five months of starting a GLP-1 or dual-agonist medication, even while their glucose and lipids improved. Four patients is a signal to investigate, not a finding to plan around, and it should not be read as evidence that these medications raise uric acid.<\/p>\n A meta-analysis of GLP-1 medications and uric acid is also often cited. Its before-and-after figures showed a reduction, but its placebo-controlled comparison did not reach significance, so it does not establish an effect against placebo either way.<\/p>\n Put together: the net direction looks favourable, the early months may be a different story for some people, and nobody can give you a percentage.<\/p>\n Not a reason to avoid treatment. A reason to plan for the first few months.<\/p>\n Tell your prescriber you have gout before you start.<\/strong> Including how often you flare, when the last one was, and what you take for it. This is the single most important step and it is routinely skipped because gout does not feel related to a weight medication.<\/p>\n Ask about monitoring uric acid early<\/strong>, rather than only if something happens. If you have a history of gout or known high uric acid, a baseline and a check during the first few months is a reasonable request.<\/p>\n Do not stop your gout medication.<\/strong> If you take something to lower uric acid, weight loss is not a reason to come off it, and the losing phase is the worst possible time to try. Any change there is a decision for the clinician who prescribes it.<\/p>\n Have your flare plan in place before you need it.<\/strong> Know what you take, that you have it, and when to call. Scrambling for this during an attack is miserable and avoidable.<\/p>\n Stay hydrated.<\/strong> Dehydration concentrates uric acid, and these medications can dehydrate you through their gastrointestinal effects. This overlaps with nearly every other piece of advice about taking them, and it matters more here.<\/p>\n Consider this scenario: someone with a gout history starts treatment, loses weight quickly over four months, and has their first flare in two years during month three. They assume the medication caused it and stop taking it. The likelier explanation is the rate of loss rather than the drug, which means the answer was to slow the loss and manage the flare, not to abandon a treatment that would probably have improved their gout over the following year.<\/p>\n If there is one adjustable thing here, it is speed.<\/p>\n Fast loss is what drives the ketone-related rise. So if you have gout and weight is coming off very quickly, that is worth raising for this reason alongside the others. Holding at a dose rather than moving up, or moving up more slowly, is a normal adjustment. Our guide on the Ozempic starting dose<\/a> covers the early progression, and there is no rule that faster is better.<\/p>\n Keeping some record helps, because “am I losing too fast” is hard to answer from memory and it is the question underneath this. Our guide on tracking your progress<\/a> covers what is worth writing down.<\/p>\n You have a flare during treatment, your joints are painful or swollen in a new pattern, you have a gout history and nobody has checked your uric acid, you are losing weight faster than intended, or you are unsure whether to continue your gout medication. That last one has a clear answer and it is not one to guess at.<\/p>\n Get urgent care<\/strong> for a hot, swollen, exquisitely painful joint with fever, because a joint infection can look like a gout flare and is a different emergency.<\/p>\nWhat the evidence supports<\/h2>\n
What is known specifically about these medications<\/h2>\n
What this means if you already have gout<\/h2>\n
The rate of loss is the lever<\/h2>\n
Contact your provider if<\/h2>\n